Over the past month, MMS shares have shown an upward bias, trading in a range that points to steady investor confidence in government services demand. The stock's move reflects resilient federal and state program activity, margin improvement in core segments, and ongoing execution on technology-driven efficiency efforts rather than one standout news item.
Sentiment in the government technology and business-process services sector has stayed constructive, backed by sustained federal and state spending on health and human services programs. Within that setting, MMS has drawn attention for its ability to turn a sizable contract pipeline into revenue while navigating near-term uncertainty around one of its largest federal contracts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Maximus, Inc. is a leading provider of technology-enabled services to government agencies, headquartered in the Tysons, Virginia area. The company operates through three reportable segments: U.S. Federal Services, U.S. Services, and Outside the U.S. Its work covers program operations and management, clinical services, employment services, appeals and assessments, and advanced technology solutions across areas such as Medicaid, Medicare, the Children's Health Insurance Program, SNAP, and veterans' disability examinations.
Key competitive strengths include deep expertise in administering complex government programs, long-standing customer relationships, and a conflict-free operating model that positions it as a trusted, independent partner. Maximus generated revenue of about $5.43 billion in fiscal 2025 and maintains a substantial multi-billion-dollar sales pipeline, which management continues to convert through new awards and rebids. Investors follow the stock closely for its predictable, recurring revenue profile, margin trajectory, and capital-return discipline.
Several verified factors have shaped MMS shares in recent weeks. The company's fiscal 2026 third-quarter results showed revenue of approximately $1.28 billion and adjusted diluted EPS of $2.22, an improvement from the prior-year period, with adjusted EBITDA margin expanding year over year.
The most notable development was the Department of Veterans Affairs' temporary pause on performance incentives and disincentives for its Medical Disability Exam program, effective July 1. Because Maximus had been recording positive performance incentives in earlier quarters, the change led management to remove assumed incentive contributions from its fourth-quarter forecast, lowering full-year adjusted EPS guidance by approximately $0.35 per share. Revenue guidance was reiterated, underscoring that the impact is concentrated on profitability rather than the underlying demand for services.
Offsetting this headwind, the company continues to emphasize AI and automation as margin drivers. Management has highlighted the SNAP-focused Accuracy Assistant, an AI-powered tool for detecting data inconsistencies, and Total Experience Management, a contact-center platform described by federal customers as a sophisticated use of AI. A refreshed $400 million share-repurchase authorization and an unchanged $0.33 quarterly dividend further signal confidence in cash generation and shareholder returns.
Looking ahead, the key variable for Maximus is the outcome and timing of the rebid for its Veterans Affairs Medical Disability Exam contract, which is scheduled to conclude at the end of 2026. The VA has released a draft performance work statement for the successor contract, and any extension or formal award timeline will be closely watched given the program's importance to the U.S. Federal Services segment.
Investors should also monitor the trajectory of AI and automation adoption across the company's programs, since efficiency gains have been a primary driver of margin expansion. On the state side, implementation of Medicaid community engagement requirements and SNAP-related initiatives tied to recent legislation could support U.S. Services revenue growth as states finalize regulations and move toward procurement. Macroeconomic considerations, including government funding priorities and the pace of contract awards, remain relevant, as do collection trends reflected in days sales outstanding. As always, these factors present both opportunities and risks that warrant ongoing evaluation rather than a single directional assumption.
In my own analysis, I have found Tickeron’s AI Trading Bots helpful for tracking momentum signals and comparing automated strategies across different timeframes. The platform offers a range of bots that apply algorithmic approaches to thousands of tickers, allowing investors to review performance metrics and strategy details without replacing their own research process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Be on the lookout for a price bounce soon.
The 10-day moving average for MMS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +1.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMS advanced for three days, in 157 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 100 of 186 cases where MMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for MMS moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 17 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMS as a result. In 53 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for MMS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 24 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
MMS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.970) is normal, around the industry mean (5.887). P/E Ratio (9.604) is within average values for comparable stocks, (33.618). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (1.946). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. P/S Ratio (0.604) is also within normal values, averaging (9.907).
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of business process services to government health and human services agencies
Industry OfficeEquipmentSupplies